Developing a new type of vaccine to generate broad antibodies against HIV-1
Official title: Nanovaccine for Eliciting bnAbs Against HIV-1
Funded at Neovaxsyn, INC. · NIH-11172343 · Data updated 2026-11-12
This study is testing a new type of vaccine that uses tiny particles to help your body fight HIV better, aiming to boost your immune system to produce strong antibodies that can protect you from the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Neovaxsyn, INC. NIH-funded |
| Lab location | 1 site (Ames, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $2,000,000 |
| NIH project number | 75N93024C00019-0-9999-1 |
| Project ID | NIH-11172343 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research would be individuals at high risk for HIV infection or those who are HIV-negative but may benefit from preventive vaccination.
✕Less likely to help
Patients who are already living with HIV or those who have a compromised immune system may not benefit from this research.
What this research studies
This research focuses on creating a novel vaccine that uses nanoparticles to deliver HIV immunogens effectively. By optimizing the delivery of these immunogens, the goal is to stimulate the immune system to produce broadly neutralizing antibodies (bnAbs) against HIV-1. The approach involves using lipid- and polymer-based nanoparticles to enhance the immune response, which has shown promise in animal studies. If successful, this could lead to a more effective HIV vaccine that better protects individuals from the virus.
Why it matters
Potential benefit: If successful, this research could lead to a more effective HIV vaccine that generates strong immune responses and provides better protection against HIV-1.
How similar studies have gone: Previous research using nanoparticle-based vaccine delivery systems has shown promising results in animal models, indicating potential for success in human applications.
Where this research is happening
-
Neovaxsyn, INC.
Ames, United States Active
Researchers
- Principal investigator: Raychaudhuri, Santanu — Neovaxsyn, INC.
- Study coordinator: Raychaudhuri, Santanu
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.